MA37661B1 - Formulation pour implant contenant de la palipéridone - Google Patents

Formulation pour implant contenant de la palipéridone

Info

Publication number
MA37661B1
MA37661B1 MA37661A MA37661A MA37661B1 MA 37661 B1 MA37661 B1 MA 37661B1 MA 37661 A MA37661 A MA 37661A MA 37661 A MA37661 A MA 37661A MA 37661 B1 MA37661 B1 MA 37661B1
Authority
MA
Morocco
Prior art keywords
paliperidone
weeks
lactic acid
formulation containing
glycolic acid
Prior art date
Application number
MA37661A
Other languages
English (en)
Other versions
MA37661A1 (fr
Inventor
Aduriz Ibon Gutierro
Rodríguez Guillermo Franco
Original Assignee
Laboratorios Farmacéuticos Rovi S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47074463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA37661(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Farmacéuticos Rovi S A filed Critical Laboratorios Farmacéuticos Rovi S A
Publication of MA37661A1 publication Critical patent/MA37661A1/fr
Publication of MA37661B1 publication Critical patent/MA37661B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Cette invention concerne une composition retard injectable par voie intramusculaire adaptée à former in situ un implant solide dans un corps. La composition comprend de la palipéridone (médicament) et/ou ses sels pharmaceutiques acceptables, quelle que soit leur combinaison, un copolymère biocompatible à base d'acide lactique et d'acide glycolique dont le rapport monomère acide lactique sur acide glycolique se situe dans la plage 50:50, et du dmso pour solvant. La composition libère la palipéridone immédiatement et en continu pendant au moins 8 semaines, son profil pharmacocinétique in vivo permettant que la formulation soit administrée toutes les 8 semaines ou sur des périodes plus longues.
MA37661A 2012-05-31 2014-12-16 Formulation pour implant contenant de la palipéridone MA37661B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12170366.4A EP2529757B1 (fr) 2011-05-31 2012-05-31 Formulation d'implant de Paliperidone
PCT/EP2013/061319 WO2013178811A1 (fr) 2012-05-31 2013-05-31 Formulation pour implant contenant de la palipéridone

Publications (2)

Publication Number Publication Date
MA37661A1 MA37661A1 (fr) 2016-03-31
MA37661B1 true MA37661B1 (fr) 2016-12-30

Family

ID=47074463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37661A MA37661B1 (fr) 2012-05-31 2014-12-16 Formulation pour implant contenant de la palipéridone

Country Status (29)

Country Link
EP (1) EP2529757B1 (fr)
JP (1) JP6430933B2 (fr)
KR (1) KR101892496B1 (fr)
CN (2) CN109966239A (fr)
AU (1) AU2013269546B2 (fr)
BR (1) BR112014029208B1 (fr)
CA (1) CA2874702C (fr)
CL (1) CL2014003215A1 (fr)
CO (1) CO7160109A2 (fr)
CY (1) CY1114975T1 (fr)
DK (1) DK2529757T3 (fr)
EA (1) EA029921B1 (fr)
ES (1) ES2456917T3 (fr)
HR (1) HRP20140158T1 (fr)
IL (1) IL235850A0 (fr)
IN (1) IN2014DN10673A (fr)
MA (1) MA37661B1 (fr)
MX (1) MX365097B (fr)
MY (1) MY181549A (fr)
NZ (1) NZ703319A (fr)
PH (1) PH12014502668A1 (fr)
PL (1) PL2529757T3 (fr)
PT (1) PT2529757E (fr)
SG (1) SG11201407971QA (fr)
SI (1) SI2529757T1 (fr)
SM (1) SMT201400044B (fr)
UA (1) UA115987C2 (fr)
WO (1) WO2013178811A1 (fr)
ZA (1) ZA201409297B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10335366B2 (en) 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US10285936B2 (en) 2010-05-31 2019-05-14 Laboratorios Farmacéuticos Rovi, S.A. Injectable composition with aromatase inhibitor
US10350159B2 (en) 2010-05-31 2019-07-16 Laboratories Farmacéuticos Rovi, S.A. Paliperidone implant formulation
HUE057236T2 (hu) 2010-05-31 2022-04-28 Farm Rovi Lab Sa Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz
US10463607B2 (en) 2010-05-31 2019-11-05 Laboratorios Farmaceutics Rofi S.A. Antipsychotic Injectable Depot Composition
PL2394664T3 (pl) 2010-05-31 2016-12-30 Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu
US10881605B2 (en) 2010-05-31 2021-01-05 Laboratorios Farmaceuticos Rovi, S.A. Methods for the preparation of injectable depot compositions
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
LT3280416T (lt) * 2015-04-07 2020-06-25 Janssen Pharmaceuticals, Inc. Ilgo veikimo injekcinių paliperidono esterių praleistų dozių dozavimo režimai
CN106038569A (zh) * 2016-05-26 2016-10-26 湖南赛沃药业有限公司 一种帕利哌酮植入剂及其制备方法
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
SI3506921T1 (sl) * 2016-08-31 2023-10-30 Mapi Pharma Ltd. Depojski sistemi, ki vsebujejo glatiramer acetat
US11666573B2 (en) * 2017-10-27 2023-06-06 Geneora Pharma (Shijiazhuang) Co., Ltd. Dosage regimen of paliperidone palmitate extended-release injectable suspension
WO2019226519A1 (fr) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Dispositif implantable pour la libération prolongée d'un composé médicamenteux macromoléculaire
SG11202005947RA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
WO2019222856A1 (fr) 2018-05-24 2019-11-28 Nureva Inc. Procédé, appareil et supports lisibles par ordinateur pour gérer des sources sonores semi-constantes (persistantes) dans des zones de capture/foyer de microphones
JP2023551009A (ja) 2020-11-30 2023-12-06 ヤンセン ファーマシューティカ エヌ.ベー. 持続放出パリペリドン注射可能製剤に関連する投与レジメン
CN116507320A (zh) 2020-11-30 2023-07-28 詹森药业有限公司 与延长释放帕潘立酮可注射制剂相关的给药方案
JP2023552329A (ja) 2020-11-30 2023-12-15 ヤンセン ファーマシューティカ エヌ.ベー. 持続放出パリペリドン注射可能製剤に関連する投与レジメン
TW202313047A (zh) 2021-09-21 2023-04-01 西班牙商禾霏藥品實驗室有限公司 抗精神病可注射儲積型組合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2819769C (fr) * 2003-07-18 2016-06-28 Oakwood Laboratories, L.L.C. Methode pour empecher la perte de poids moleculaire des polymeres, la formation d'impuretes et la gelification dans les composes polymeriques
NZ552841A (en) 2004-08-04 2009-07-31 Alza Corp Controlled release dosage form comprising two layers, wherein the delay layer is substanially free of non-microencapsulated drug
US8852638B2 (en) * 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
DK2154138T3 (en) 2007-04-19 2015-11-02 Youxin Li Novel compounds for the treatment of psychotic disorders, methods of preparation and uses thereof
BRPI0811319A2 (pt) * 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US20090036470A1 (en) 2007-07-27 2009-02-05 Jiri Bartl Paliperidone derivatives
DK2234617T3 (da) 2007-12-19 2021-05-25 Janssen Pharmaceutica Nv Doseringsskema forbundet med langtidsvirkende injicerbare paliperidonestere
EP2485712A1 (fr) 2009-10-06 2012-08-15 Ascendis Pharma A/S Composition sous-cutanée de palipéridone
PL2394664T3 (pl) 2010-05-31 2016-12-30 Preparat przeciwpsychotyczny do wstrzykiwań o przedłużonym uwalnianiu
HUE057236T2 (hu) * 2010-05-31 2022-04-28 Farm Rovi Lab Sa Készítmények befecskendezhetõ in-situ biológiailag lebontható implantátumokhoz
DK2529756T3 (da) * 2011-05-31 2021-08-02 Farm Rovi Lab Sa Risperidon- og/eller paliperidon-implantatformulering
SI2529757T1 (sl) * 2011-05-31 2014-05-30 Laboratorios Farmaceuticos Rovi, S.A. Formulacija paliperidon implantata

Also Published As

Publication number Publication date
EP2529757B1 (fr) 2014-01-08
AU2013269546B2 (en) 2017-12-14
MX365097B (es) 2019-05-22
PH12014502668B1 (en) 2015-02-02
SMT201400044B (it) 2014-05-07
JP6430933B2 (ja) 2018-11-28
ZA201409297B (en) 2015-12-23
CA2874702C (fr) 2021-05-11
CO7160109A2 (es) 2015-01-15
EA029921B1 (ru) 2018-05-31
CN109966239A (zh) 2019-07-05
HRP20140158T1 (hr) 2014-04-25
KR101892496B1 (ko) 2018-10-04
WO2013178811A1 (fr) 2013-12-05
DK2529757T3 (en) 2014-02-24
PT2529757E (pt) 2014-02-27
PH12014502668A1 (en) 2015-02-02
CN104349792A (zh) 2015-02-11
JP2015518035A (ja) 2015-06-25
CY1114975T1 (el) 2016-12-14
BR112014029208A2 (pt) 2017-06-27
MA37661A1 (fr) 2016-03-31
IL235850A0 (en) 2015-01-29
PL2529757T3 (pl) 2014-04-30
EA201401348A1 (ru) 2015-04-30
CA2874702A1 (fr) 2013-12-05
NZ703319A (en) 2016-12-23
AU2013269546A1 (en) 2015-01-22
MX2014014484A (es) 2015-02-24
KR20150015020A (ko) 2015-02-09
CL2014003215A1 (es) 2015-07-10
SI2529757T1 (sl) 2014-05-30
UA115987C2 (uk) 2018-01-25
IN2014DN10673A (fr) 2015-08-28
BR112014029208B1 (pt) 2020-04-07
SG11201407971QA (en) 2014-12-30
EP2529757A1 (fr) 2012-12-05
ES2456917T3 (es) 2014-04-24
MY181549A (en) 2020-12-28

Similar Documents

Publication Publication Date Title
MA37661B1 (fr) Formulation pour implant contenant de la palipéridone
MA37664B1 (fr) Formulation pour implant contenant de la rispéridone et/ou de la palipéridone
RS53205B (en) IMPLANTABLE PALIPERIDON FORMULATION
MA34296B1 (fr) Composition retard injectable antipsychotique
CY1120761T1 (el) Ενεσιμη συνθεση αιωρηματος που αποτελειται απο βουπρενορφινη
CY1112499T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
EP4292588A3 (fr) Administration d'agents de potentialisation de cftr modifiés au deutérium
ECSP088240A (es) Composición de trazodona para administración una vez por día
MX2009003735A (es) Composicion en deposito inyectable y su procedimiento de preparacion.
WO2007145991A3 (fr) Compositions anti-inflammatoires et analgésiques et procédés associés
EA200870368A1 (ru) Антибиотические композиции с модифицированным высвобождением и способ их получения
JP2010530376A5 (fr)
UA92030C2 (ru) Фармацевтические композиции регулированного высвобождения нестабильных в кислой среде лекарственных средств
BRPI0906866A2 (pt) métodos e composições para administração oral de agentes terapêutico de proteína e peptídeo
RU2014102940A (ru) Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
EP1864976A4 (fr) Dérivé de propane-1,3-dione ou sel de celui-ci
EP4306113A3 (fr) Composition pharmaceutique pour administration orale comprenant un dérivé d'aminopyrimidine ou son sel
MX2021006036A (es) Formulacion inyectable de liberacion sostenida de naltrexona.
SA520411067B1 (ar) تركيبات صلبة فموية من بيتا هستين ممتدة الإطلاق غير نابضة
TN2013000480A1 (fr) Composition pharmaceutique effervescente à base de sildénafil et son procédé de fabrication